Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market size is anticipated to grow at substantial growth rate during the forecast period i.e., between 2025-2037.
The LHRH-agonist therapy is widely used for patients with prostate cancer. In males, LHRH agonist manages the growth of prostate cancer by stopping normal hormonal functions in the body. Initially, LHRH agonist stimulates the production of testosterone for a couple of weeks and when the LHRH agonist reaches an elevated level, the human body stops the production of new LHRH. Owing to the consequence, there is no more production of testosterone in the body and low levels of testosterone drops the level of prostate cancer cells in the body. The market is thriving primarily on account of the growing cases of prostate cancer in males.
-Agonists-Market-Size.jpg)
Luteinizing Hormone Releasing Hormone (LHRH) Agonists Sector: Growth Drivers and Challenges
Growth Drivers
- High Effectiveness of LHRH Agonists in Prostate Cancer
- Rising Advancements in the Healthcare Industry
Challenges
- Side Effects Related to LHRH Agonists
Luteinizing Hormone Releasing Hormone (LHRH) Agonists Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
|
|
Base Year Market Size (2024) |
|
|
Forecast Year Market Size (2037) |
|
|
Regional Scope |
|
Luteinizing Hormone Releasing Hormone (LHRH) Agonists Segmentation
The luteinizing hormone releasing hormone (lhrh) agonists market is segmented by drug type into Eligard, Zoladex, Lupron, Vantas and others. Amongst these segments, the Eligard segment is projected to grab a significant market share in the year 2021. The growth of the segment can be attributed to the rising usage of the drug for the treatment of prostate cancer.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Type |
|
|
By Patient Type |
|
|
By End Users |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportLuteinizing Hormone Releasing Hormone (LHRH) Agonists Industry - Regional Synopsis
Regionally, the luteinizing hormone releasing hormone (lhrh) agonists marketis segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
The market for LHRH agonists in North America industry is predicted to dominate majority revenue share by 2037, owing to rising incidence rate of prostate cancer in the region, along with increasing investments for the development of targeted drug therapies to treat prostate cancer. Alternatively, the market in the Asia Pacific region is estimated to be the fastest growing by recording a significant CAGR during the forecast period on the back of growing awareness for the treatment of prostate cancer coupled with the improvements in healthcare infrastructure. Further, collaborations of key players with various government institutions for the treatment of prostate cancer along with the presence of online portals providing detailed information regarding luteinizing hormone releasing hormone agonists is also anticipated to foster the luteinizing hormone releasing hormone (lhrh) agonists market growth over the forecast period.
Companies Dominating the Luteinizing Hormone Releasing Hormone (LHRH) Agonists Landscape
- F. Hoffmann-La Roche Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis Pharmaceuticals Corporation
- Siemens Healthcare Private Limited
- Pfizer Inc.
- Clovis Oncology
- Genomic Health, Inc.
- Myriad Genetics, Inc.
- MDxHealth
- Tolmar Pharmaceuticals, Inc.
- Ferring B.V.
In the News
Author Credits: Radhika Pawar
- Report ID: 3037
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
